Horizon Discovery and Bayer have teamed up to develop cell lines that more accurately model disease-relevant mutations.
Using Horizon’s precision genome editing technology, GENESIS, the collaboration with aim to deliver high quality cell lines that more accurately model the disease-relevant mutations found in human tumors.
With the technology, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly and without unwanted and confounding genotypes and/or phenotypes.
With the ability to rapidly introduce one or more significant gain-of-function disease-relevant mutations (common in many forms of cancer), as well as loss-of-function alterations, into any endogenous gene loci of human cells, GENESIS can reflect patient genotypes in human cancer cell lines derived from human tumors.
Under the terms of the agreement, Horizon will apply GENESIS to develop human isogenic cell lines for use in Bayer’s oncology research and development programs.
